Katia Paciaroni
International Centre for Transplantation in Thalassemia and Sickle Cell Anaemia, Mediterranean Institute of Haematology, Policlinic of “Tor Vergata” University, Rome, Italy
Gioia De Angelis
International Centre for Transplantation in Thalassemia and Sickle Cell Anaemia, Mediterranean Institute of Haematology, Policlinic of “Tor Vergata” University, Rome, Italy
Cristiano Gallucci
International Centre for Transplantation in Thalassemia and Sickle Cell Anaemia, Mediterranean Institute of Haematology, Policlinic of “Tor Vergata” University, Rome, Italy
Cecilia Alfieri
Michela Ribersani
International Centre for Transplantation in Thalassemia and Sickle Cell Anaemia, Mediterranean Institute of Haematology, Policlinic of “Tor Vergata” University, Rome, Italy
Andrea Roveda
International Centre for Transplantation in Thalassemia and Sickle Cell Anaemia, Mediterranean Institute of Haematology, Policlinic of “Tor Vergata” University, Rome, Italy
Antonella Isgrò
International Centre for Transplantation in Thalassemia and Sickle Cell Anaemia, Mediterranean Institute of Haematology, Policlinic of “Tor Vergata” University, Rome, Italy
Marco Marziali
International Centre for Transplantation in Thalassemia and Sickle Cell Anaemia, Mediterranean Institute of Haematology, Policlinic of “Tor Vergata” University, Rome, Italy
Ivan Pietro Aloi
Departments of Surgery, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy
Alessandro Inserra
Departments of Surgery, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy
Javid Gaziev
International Centre for Transplantation in Thalassemia and Sickle Cell Anaemia, Mediterranean Institute of Haematology, Policlinic of “Tor Vergata” University, Rome, Italy
Pietro Sodani
International Centre for Transplantation in Thalassemia and Sickle Cell Anaemia, Mediterranean Institute of Haematology, Policlinic of “Tor Vergata” University, Rome, Italy
Guido Lucarelli
International Centre for Transplantation in Thalassemia and Sickle Cell Anaemia, Mediterranean Institute of Haematology, Policlinic of “Tor Vergata” University, Rome, Italy
Keywords
Sickle Cell Anaemia- Aspergillus Infection-Bone Marrow Transplant
Abstract
Sickle Cell Anaemia (SCA) is the most common inherited blood disorder and is associated with severe morbidity and decreased survival. Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) is the only curative approach. Nevertheless the decision to perform a marrow transplant includes the risk of major complications and mortality transplant related. The infections represent the main cause of mortality for SCA patients undergoing transplant. Invasive Pulmonary Aspergillosis (IPA) is a devastating opportunistic infection and remains a significant cause of morbidity and mortality in HSCT recipients. Data regarding IPA in the setting of SCA are lacking. In the present report, we describe a patient with SCA who developed IPA after allogeneic bone marrow transplant. The fungal infection was treated by systemic antifungal therapy in addition to the surgery, despite mild chronic GVHD and with continuing immunosuppression therapy. This case shows that IPA occurring in bone marrow recipient with SCA can be successful treated
